Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Active-controlled, Phase III Clinical Trial to Evaluate the Efficacy and Safety of BPDO-1603 in Patients With Moderate-to-severe Alzheimer's Disease

NCT04229927 is registered in ClinicalTrials.gov with Hyundai Pharmaceutical Co., LTD. as lead sponsor.

NCT NCT04229927
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04229927 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Active-controlled, Phase III Clinical Trial to Evaluate the Efficacy and Safety of BPDO-1603 in Patients With Moderate-to-severe Alzheimer's Disease
Lead sponsor
Hyundai Pharmaceutical Co., LTD.
Phase
Phase 3
Overall status
Unknown status
Start date
February 27, 2020
Completion date
March 1, 2023
Enrollment
712 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

moderate-to-severe alzheimer's disease